4 unknown, 3 active not recruiting, 3 completed, 1 recruiting. 11 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Unknown 4, Active not recruiting 3, Completed 3, Recruiting 1 |
| Phase 2 | 3 | Unknown 2, Completed 1 |
Follow Immunogenicity: new trials by email Literature Review of Immunogenicity trials Research Report on Immunogenicity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Influenza Vaccination Strategy for Patients With Hematologic Malignancy High-dose trivalent inactivated influenza vaccine (HD-IIV3), MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4), Standard-dose trivalent inactivated influenza vaccine (SD-IIV3) - Hematologic Neoplasms, Influenza | Phase 3 | Recruiting | Asan Medical Center | 120 | 2025-12-04 | 2026-09-01 |
| Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC MVA-BN standard regimen, MVA-BN standard regimen (Administered as PEP) - Neonate, Maternal Transmission | Phase 3 | Active not recruiting | Jean-Pierre Van geertruyden | 359 | 2025-06-23 | 2026-01-30 |
| Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC MVA-BN standard regimen, MVA-BN half-dose regimen - Mpox (Monkeypox), Vaccination | Phase 3 | Active not recruiting | Jean-Pierre Van geertruyden | 344 | 2025-05-29 | 2026-04-29 |
| A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2 Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2; - Immunogenicity, Safety | Phase 2 / Phase 3 | Unknown | Stemirna Therapeutics | 800 | 2023-06-20 | 2023-06-20 |
| Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia GP404141, Nplate - Drug Effect, Safety Issues | Phase 3 | Active not recruiting | Geropharm | 160 | 2023-04-04 | 2024-07-11 |
| mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs SW-BIC-213;SARS-Cov-2., Sinopharm (BIBP);SARS-Cov-2., Pfizer(BNT162b2);SARS-Cov-2. - Immunogenicity, Safety | Phase 3 | Unknown | Stemirna Therapeutics | 600 | 2022-10-19 | 2023-01-17 |
| New Generation mRNA Booster Vaccine Against Emerging VOCs SW-BIC-213, SARS-Cov-2 Vaccina(Vero Cell ) Inactivated - Immunogenicity, Efficacy | Phase 3 | Unknown | Stemirna Therapeutics | 2000 | 2022-10-01 | 2023-04-12 |
| Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B Recombinant Hepatitis B + DTP-HB-Hib, Hep B + Pentabio (registered) - Immunogenicity, Safety | Phase 3 | Completed | PT Bio Farma | 220 | 2020-10-13 | 2022-01-18 |
| Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III) Vi-DT Typhoid Conjugate Vaccine, PQed Typhoid Conjugate Vaccine, Vi Polysaccharide Vaccine - Safety Issues, Immunogenicity | Phase 3 | Completed | PT Bio Farma | 3071 | 2020-03-02 | 2022-01-04 |
| Protectivity and Safety Following Recombinant Hepatitis B Vaccine Recombinant Hepatitis B vaccine, Recombinant Hepatitis B (Bio Farma) - Immunogenicity | Phase 2 / Phase 3 | Completed | PT Bio Farma | 536 | 2019-09-11 | 2022-09-19 |
| Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Trivivac vaccine - Immunogenicity, Reactogenicity | Phase 2 / Phase 3 | Unknown | Queen Sirikit National Institute of Child Health | 200 | 2012-09-01 | 2013-01-08 |
Mpox, Monkeypox (2) · Smallpox (2) · Hematologic Neoplasms (1) · Influenza, Human (1) · Measles (1) · Rubella (1)
Infections (4) · Virus Diseases (4) · Animal Diseases (2) · DNA Virus Infections (2) · Poxviridae Infections (2) · Primate Diseases (2) · RNA Virus Infections (2) · Rodent Diseases (2) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Mononegavirales Infections (1) · Morbillivirus Infections (1) · Neoplasms (1) · Neoplasms by Site (1) · Orthomyxoviridae Infections (1)
Hepatitis B Vaccines (1) · Vi polysaccharide vaccine, typhoid (1) · romiplostim (1)
PT Bio Farma (3) · Stemirna Therapeutics (3) · Jean-Pierre Van geertruyden (2) · Asan Medical Center (1) · Geropharm (1) · Queen Sirikit National Institute of Child Health (1)
Indonesia (3) · Democratic Republic of the Congo (2) · Laos (2) · Russia (1) · South Korea (1) · Thailand (1)
Mayfong Mayxay, doctor (3) · Bernie E Medise, MD (1) · Bulat Bakirov, MD (1) · Dmitry Kirtbaya (1) · Eddy Fadliyana (1) · Elena Borisenkova (1) · Galina Salogub (1) · Igor Davydkin (1) · Olga Vinogradova (1) · Sung-Han Kim, MD, PhD (1) · Yetty M Nency, MD (1)